Render Target: STATIC
Render Timestamp: 2024-12-09T11:41:24.511Z
Commit: 224419269841c11382c4555dbee545259bf6c379
XML generation date: 2024-09-20 06:22:42.571
Product last modified at: 2024-11-27T14:30:10.735Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: FastScan ELISA Kit
PDP - Template ID: *******a26362b

FastScan Cas9 (S. pyogenes) ELISA Kit #29666

Filter:
  • ELISA

    Supporting Data

    REACTIVITY All
    Application Key:
    • ELISA-ELISA 
    Species Cross-Reactivity Key:
    • All-All Species Expected 

    Product Information

    Product Description

    The FastScan™ Cas9 (S. pyogenes) ELISA Kit is a sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of Cas9 (S. pyogenes). To perform the assay, sample is incubated with a capture antibody conjugated with a proprietary tag and a second detection antibody linked to HRP, forming a sandwich with Cas9 (S. pyogenes) in solution. This entire complex is immobilized to the plate via an anti-tag antibody. The wells are then washed to remove unbound material. TMB is then added. The magnitude of observed signal is proportional to the quantity of Cas9 (S. pyogenes).

    *Antibodies in kit are custom formulations specific to kit.

    IMPORTANT: This FastScan™ ELISA Kit requires 4 washes at Step 6 of the protocol.

    Protocol

    Specificity / Sensitivity

    The FastScan™ Cas9 (S. pyogenes) ELISA Kit detects endogenous levels of Cas9 (S. pyogenes), as shown in Figure 1. This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.

    Species Reactivity:

    All Species Expected

    Background

    The CRISPR associated protein 9 (Cas9) is an RNA-guided DNA nuclease and part of the Streptococcus pyogenes CRISPR antiviral immunity system that provides adaptive immunity against extrachromosomal genetic material (1). The CRISPR antiviral mechanism of action involves three steps: (i), acquisition of foreign DNA by host bacterium; (ii), synthesis and maturation of CRISPR RNA (crRNA) followed by the formation of RNA-Cas nuclease protein complexes; and (iii), target interference through recognition of foreign DNA by the complex and its cleavage by Cas nuclease activity (2). The type II CRISPR/Cas antiviral immunity system provides a powerful tool for precise genome editing and has potential for specific gene regulation and therapeutic applications (3). The Cas9 protein and a guide RNA consisting of a fusion between a crRNA and a trans-activating crRNA (tracrRNA) must be introduced or expressed in a cell. A 20-nucleotide sequence at the 5' end of the guide RNA directs Cas9 to a specific DNA target site. As a result, Cas9 can be "programmed" to cut various DNA sites both in vitro and in cells and organisms. CRISPR/Cas9 genome editing tools have been used in many organisms, including mouse and human cells (4,5). Research studies demonstrate that CRISPR can be used to generate mutant alleles or reporter genes in rodents and primate embryonic stem cells (6-8).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    FastScan™ ELISA is a registered trademark of Cell Signaling Technology, Inc.
    U.S. Patents 9,086,407, 9,261,500, and 9,476,874, foreign equivalents, and child patents deriving therefrom.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.